The report showcases drugs entering the market in 2021 with potential to realize 1 billion USD annual sales within five years
Of all the drugs anticipated to launch in a given year, how are potential blockbusters selected?
Answering that question is both a science and an art. The data and analysis used to identify the Drugs to Watch drew from Clarivate life sciences solutions and integrated data sets that span the R&D and commercialization lifecycle as well as expert evaluation.
Scroll down to see how we do that or download the full report on PDF.
To create an initial shortlist, we select drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched early in 2021, including drugs launched for a new indication that could be particularly impactful on the industry. Drugs launched prior to 2021 were excluded.
Our experts then manually evaluated each drug in its individual context, based on: factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other factors.
Please note that Clarivate analysts generated the data shown in this report on January 21, 2021 and the data were correct as of that time.
This year’s Drugs to Watch also includes a special section on the COVID-19 vaccine landscape, which summarizes the vaccines that were granted emergency use authorizations/conditional approvals as of February 10, 2021.